National Laboratories Programme Minutes · PH welcomed everyone to the meeting. Introductions were done and apologies noted. 2. Minutes of Last Meeting & Matters Arising The minutes

Chair Professor Elizabeth Ireland Chief Executive Colin Sinclair NHS National Services Scotland is the common name of the Common Services Agency for the Scottish Health Service.

Minutes

National Laboratories Programme Gyle Square 1 South Gyle Crescent Edinburgh EH12 9EB Email: [email protected] Website : https://www.labs.scot.nhs.uk/

Meeting: Laboratories Oversight Board (LOB) – Meeting 9 Date/Time: 17th July 2019, 1000-1200 Location: Boardroom 1&2, Gyle Square, Edinburgh Chair: Paul Hawkins, Chief Executive, NHS Fife Present: BB Bill Bartlett, Clinical Lead, National Laboratories Programme Team MC Martin Connor, Laboratory Medicine Clinical Lead, West Region ED Ellie Dow, joint Laboratory Medicine Clinical Lead, North Region LF Liz Furrie, joint Laboratory Medicine Clinical Lead, North Region DG Donna Galloway, Representative of the East Laboratory Medicine Operational Board MG Mike Gray, Laboratory Service Manager, East Region JH Jessica Henderson, Programme Director, National Laboratories Programme Team PH Paul Hawkins, Chief Executive, NHS Fife and LOB Chair IJ Ingo Johannessen, Laboratory Medicine Clinical Lead, East Region IMcG Irene McGonnigle, Planning Representative, West Region MM Mary Morgan, Director of Strategy, Performance and Service Transformation CS Charlotte Syme, Deputy Clinical Lead, National Laboratories Programme Team VS Vanessa Sandison, Representative of the North Region Laboratories Operational

Board JW Jackie Walker, Laboratory Service Manager, West Region Videoconference/Teleconference: CG Carol Goodman, Planning Representative, North Region IG Ian Godber, Chair of Diagnostic Steering Advisory Group

Guests KB Karen Burns, Project Support Officer, National Laboratories Programme SH Shirley Higgins, Project Manager, National Laboratories Programme Apologies: SA Sharon Adamson, Representative of the West Region Laboratories Operational

Board LD Linda Delgado, Partnership Representative for Laboratories JMcC Jan McClean, Planning Representative, East Region DS David Stirling, Director of Health Care Science, NSS KW Kim Walker, Programme Manager, National Laboratories Programme Team In Attendance: Jennifer Downie, Project Support Officer, National Laboratories Programme Team

mailto:[email protected]

https://www.labs.scot.nhs.uk/


1. Welcome, Introductions and Apologies

PH welcomed everyone to the meeting. Introductions were done and apologies noted.

2. Minutes of Last Meeting & Matters Arising

The minutes of the previous meeting held on 5th June 2019 were reviewed and approved as an

accurate reflection of the meeting. Actions were updated as necessary.

2.1. NSS Procurement Support

JH was able to confirm that George Futcher is the NSS procurement representative on the

LIMS board.

Since KB left his post within GG&C no-one has taken over the Digital Pathology piece of

work. This item is on the agenda for today and will be discussed in more detail.

2.2. Lab Centre Negotiations

ED gave a brief update on the Lab Centre negotiations informing the group that Clinisys

have been pushed to give dates for a meeting. A date was initially set for 6th September

but due to leave of key parties this is not suitable and there is ongoing discussions to

confirm another date which ED is hoping will be early September. DG added that Clinisys

have been pushing back when it comes to confirming a date. PH advised ED & DG that if

no date is set within the week this needs to be escalated and that he is happy to get

involved if required.

3. Performance Report

JH presented the programme reporting pack for period 01/06-05/07 to the group outlining the

key highlights and programme performance. JH brought the following notable highlights to the

attention of the group;

IT Connectivity – RAG Status Amber

Rebaselined plan for deployment and expansion plan produced and agreed with boards

Security risk assessment for NHS Forth Valley is now complete and meeting date has

been scheduled for 7th August to proceed with next steps for implementation

A solution has now been agreed for the patient identifier issue and work will commence

shortly

Meeting is scheduled for 18th July between NHS Grampian & NHS Orkney/Shetland to

further investigate the use of ICE

Standardisation – RAG Status Green

The Standardisation group met on 25th June with the next meeting scheduled for 30th

July

Agreement was made on the guiding principles for standardisation aswell as an

agreement on using SNOMEDCT as standard

Discussion took place and agreement made to amalgamate LIMS and Standardisation

groups (will also include NLIIP when work resumes)


Blueprint Development & Benefits Workstreams – RAG Status Green

Service design workshop complete in West region with a number of outputs to take

forward for all disciplines

Agreement reached that Histopathology should be the first discipline to proceed with

DSM Model

A detailed plan is being put together on how to take forward to Histopathology model,

this paper will be shared with the Blueprint Subgroup in the first instance and then

presented to LOB

It has been identified that data collection needs to be strengthened

Stakeholder Engagement & Communication – RAG Status Amber

Over the past 6 weeks JH has attended a significant number of stakeholder meetings

and event including DSG, LIMS Procurement Board, Diagnostic Workforce Planning

and Scottish Government amongst others

Healthcare Science Event took place in June where the 2nd day had a focus on

Laboratories and was chaired by JH

There will be an upcoming focus on challenges around governance, LIMS and

standardisation which need addressed to improve future discussions

Risks & Issues For this reporting period there are 2 red issues which relate to the implementation of NPEx;

Conflict between the IP address ranges used at Forth Valley (192.xx.xx.xx) and those

utilised by THIS

NPEx unlikely to provide connectivity solution for NHS Orkney and NHS Shetland with

NHS Grampian

On a broader level there are ongoing risks around the governance of the programme and around system capacity to engage.

4. Priorities & Benefits

Priorities JH has put together a proposal of the priorities that need to be addressed by March 2020 (see appendix a) The question was raised around the customer co-production workshop and what this would entail. JH confirmed that initially the team are keen to engage both Primary & Secondary Care professionals aswell as patients. JH plans to meet with Lucy Munro, Associate Director for Primary Care to test the need for co-production with primary care and how best to approach this. DG raised a concern around the timescale of the workshops as not sure what added value these will bring as the regions already meet quarterly with their stakeholders and it is unclear at this point what additional information we will have to present. JH flagged that this isn’t about presenting solutions, but engaging stakeholders to understand what does and doesn’t work within the diagnostic pathway, generating opportunities to identify new ways of working across the system. There was further discussion around the submission of Histopathology DSM Model to the LOB and JH informed the group that the Programme Team are hoping to have both an analytical and Project Management resource to deliver this work.


MG raised that part of the remit for the East region is to look at Histopathology and it needs to be clear if the regions have to progress this work or if this is going to be looked at on a national level as there is now a risk that there will be duplication of work. PH acknowledged that Histopathology should be the easiest of the disciplines to develop a DSM and that we need to take the work that has already been done in the regions and move forward on a national basis. ED added that there is a real risk of Histopathology falling over in the North region as there are now a handful of employees that are going to retire in the next few years with no clear strategy to replace them given the shortage of staff within the discipline. JW alluded to the fact that by bringing Histopathology together as a national workstream it will inevitably have an impact on the regional work plans and that there will be a number of activities required to be done prior to the submission of the model in March 2020. PH asked the members of the LOB if they are in agreement that this is the right approach to moving towards a DSM and the question is more around the how we achieve this; there was agreement from all those present and JH confirmed that she is currently working on a paper on how to progress this and can be circulated in due course. It is clear however that there will need to be a national Histopathology workshop with high quality data to present the case for change, enabling stakeholders to build the future model. PH raised the potential issue around Histopathologists carrying out post mortems, writing coroner’s reports and attending hearings, without reimbursement to Health Boards for the time taken within working hours. This needs to be factored into the planning, and provided as a reimbursed service. It was agreed that further data collection needs to be carried out in the first instance as there is variation across all the Health Boards in relation to how the service is delivered. JH emphasised that it is going to be crucial that data collection continues around the other disciplines alongside the development of the Histopathology DSM. MM added that both Immunology and Blood Transfusion may also be good disciplines to look at in the early stages. LF was able to confirm that Immunology was discussed however although they do not have a network Immunology colleagues do work as a national network and are not in as critical a state as Histopathology. IJ questioned how this will fit in with DSG and how we present the idea to them, it was confirmed that there are several members of the LOB that also attend DSG. JH provides a regular update in capacity as Programme Director so will invite feedback from the DSG on the new approach to development of the DSM.

Benefits BB gave a verbal presentation to the group on the importance of benefit and how we must begin to move forward with this piece of work. There are various tools available to help us progress this. There is ongoing work around producing an alignment tool that will be able to help us measure the hard benefits. There needs to now be a focus on how we align the driver diagram and the Blueprint to the Triple Aim Value and in turn have something to present to the Chief Executives. Work is ongoing in the North region and how the various work streams are aligning to the Triple Aim Value. There is an upcoming move from Triple Aim to Quadruple Aim which factors in staff wellbeing, and this should be incorporated into the programme. JH added that we may have to also look at softer benefits aswell as the hard benefits. It is critical that we get benefits out of the system so that we can show why we are doing what we are doing.


PH further added that we also need to look at how we make the Blueprint work within the specialities i.e. how do we use this as the strategic plan for the Histopathology piece of work. There is also a need to have very clear KPI’s for moving forward so that we can measure that things are actually working and that the value is getting all the way through to the Clinician’s and patients and not just to the laboratories.

5. Regional Leads Update

North Region The main points to note for the North region are as follows;

POCT and Infrastructure BOBSCARDs sent to Programme Board for comment/approval at 27

June 2019 meeting

Quality Workstream PID sent to Programme Board for comment and approval for at 27 June

2019 meeting

Taigh-solais Newsletter Issue 1 circulated 30 May 2019

NoSLabs Workstreams and Projects Roadmap Updated

NoSLabs Change Control Management Plan created

Risks escalated to a combined issue in relation to the resource availability to support both the

regional and national programmes, and for the prioritisation of regional objectives

There will be a reassessment of work streams and the structure of the NoS Board will be

changing

East Region

The main points to note for the East region are as follows;

Roadshows The St John’s Roadshow Event was held on 4th June 2019. The event was well attended by staff and who gave positive feedback. Regional Procurement Stage 2: Invitation to Negotiate was issued to successful bidders in March 2019. All bidders have asked for an extension to the closing date which has been given. The new closing date is 31st July 2019. LIMS Collaborative Procurement See LIMS Update.

Service Reviews East Region Lab Leads attended the West of Scotland Lab Service Design workshop to support and observe on 13th June 2019. A high-level workshop plan for the East Region has been drafted with a view to having the workshop in September 2019. Financial Modelling A scoping session was had on 27th June 2019 and the group agreed on a number of initial high-level data items to collect for the Region.


Demand Optimisation Regional Demand Optimisation Lead agreed at ELMER on 27th June 2019. A template to be developed for the region to report on progress going forward.

Regional Laboratory Customer Website Initial conversations with NHS Lothian’s website have indicated that creating an NHS Borders

and NHS Fife section on the existing is no longer an option due to NHS Lothian backend

technology being shut down. Alternative solutions are being sought.

DG added that there has also now been a first meeting to look at a costing model. MM asked the regions if any of them were using the new financial dashboard and if this was going to help. MG & DG advised MM that they hadn’t seen the new dashboard and weren’t aware of its existence. MM offered to give a quick demo following the meeting but advised it may be useful for someone to come to the next meeting to give a proper demo of the new dashboard as none of the regions were aware and will likely all see massive benefit from using it. West Region

The main points to note from the West region are as follows;

The West Region laboratories services workshop was held in Glasgow on 13th June 2019, was

attended by 100+ members of the Laboratories community and was very well received.

At the workshop delegates began to:

Explore potential future service models for Histopathology & Microbiology, with Blood Science focusing on problem statements while ensuring alignment to the national Distributed Service Model and requirements to deliver Discipline specific action plans are in development with further work to be done in follow up, discipline specific workshops/meetings to be held in the coming months as appropriate The Regional Planning team continues to facilitate and support the WLMDB in the development of the action plan. Post workshop planning meetings with Clinical Leads and our

colleagues in NSS are ongoing.

6. LIMS Governance & Delivery

The second meeting of the LIMs Board took place on 15th July. Progress is starting to take

place and there has been agreement around the procurement resource. The initial figure that

was generated for this may reduce as it has been identified that there is some already some

resource that could be utilised. MG also confirmed that due to previous work undertaken about

80% of the specification is already complete. The eHealth Leads are keen that the Outline

Business Case (OBC) is delivered by an outside agency, there was an original date set for this

to be delivered which was September 2019 however this will now be pushed out although

agreed timescales for this have not been confirmed as yet. It has been made clear that the

procurement process will begin next year. MG also confirmed that there is good buy in from

key groups such as, eHealth & IT and added that the buy in from these groups especially

eHealth is crucial to the success of the project. The governance for this project currently sits

with the 9 boards that have invested funding. An ambitious timeline has been set and there is

agreement that further discussions are required around the governance of the LIMS board.

There have been discussions around whether or not there needs to be a national view point as

whatever system is procured is going to be a long term purchase therefore the viewpoints need


to be very clear and long term. PH asked how we ensure a national perspective is kept

throughout this project as we do not want 9 boards starting the process and then 10 years later

we are in the same situation as currently with different health boards all on different instances

of LIMS, or not engaging in the work delivered by the LIMS programme. MG alluded the fact

that there will be a national framework developed which will allow those boards not currently

represented to procure further down the line without deviation from what is being procured

currently. There are ongoing discussions about how to implement the structure of a new LIMS.

IG asked if there is a need for further scoping and some lessons learned from the LIMS Project

in NHS Wales and if there would be any benefit in carrying out a SWOT analysis on the Wales

approach.

There is still a question around how the LOB wants to be included/involved with the LIMS

board. IJ raised the question as to why this project is sitting out with the National Programme

as there are very clear linkages. MG confirmed that when the National Programme was first

established it was made very clear that a national LIMS was out of scope and would not be part

of the National Programme. MM confirmed that although a national LIMS was not part of the

original scope it does make sense that this project now sits under the LOB governance going

forward and to move this forward all that would be needed is a change control to be submitted

to the transformational leads.

Given the pressing timeline and the scheduled work of the OBC MG asked for confirmation that

the current LIMS group can proceed with work to progress this. PH confirmed that yes the

group should continue as planned for now and the LOB are in no way stalling any working

planned and will have the necessary conversations with relevant groups/people on how to

progress with bringing this piece of work under the LOB governance.

MM asked MG to confirm if it will be a competitive dialogue procurement approach as this is

going to be crucial and is the only way to proceed. MG confirmed this is the approach that has

been agreed.

7. Industry SBAR

JH has drafted an Industry SBAR outlining potential funding opportunities from Scottish

Government (SG) and the recommendation for moving forward with a focus on innovation as

an enabler for the DSM. SG have intimated that they would be keen to work alongside the

Laboratory community supporting the running of a demand led approach to innovation via an

industry event. Through ongoing conversations with Andrew Fowlie at SG there has been an

indication that there could be in the region of £10,000 investment available from SG to run an

event, along with resource to support delivery,

JH proposal to the LOB is that we progress these conversations and take advantage of the

potential opportunity to work with SG. It is proposed that there is a demand led approach and

we go to the industry event with pre populated problem statements and allow industry to

cultivate solutions to given problem statements. The NLTP will be looking to hold an industry

event later in the year and will be looking for input from all the relevant disciplines.

MM added that there is a spending review underway within SG and there has been a

communication issued that SG are looking at some key areas of investment, some of which

laboratories could tap into. It is important that we look at all out possible funding options for


innovation work going forward. This opportunity will be picked up in the Clinical Leads Group

after the LOB.

JH will continue to keep the LOB informed of developments as they arise.

8. Digital Pathology

JH informed the group that over the past few weeks she has spoken to various people involved

with Digital Pathology. It has become clear that there is currently a gap on who is going to be

leading this project going forward now that KB has left his post. There has been a procurement

done however JH was not aware if there had been involvement from National Procurement, JW

was able to confirm that Jim Binney had been involved from a National perspective. JH went on

to discuss that there is a real concern that Phillips does not allow interoperability. PH added

that these issues were raised with Glasgow a while ago however it appeared that the process

was too far down the line for anything to be done about this. GB confirmed during a

conversation with JH that Digital Pathology has been implemented in Glasgow.

LF informed the group that the North Region are about to begin their own Digital Pathology

Pilot, Path Alba, which will look at a very specific remit. If the National Team leading on Digital

Pathology were interested the North would be happy for this to be used as a National pilot if

appropriate.

JH raised concern that at present we do not know if Digital Pathology offers healtheconomic

value. There was funding available for a health economic evaluation which hasn’t been

undertaken, and it would be prudent to deliver this ahead of further roll out. JH added that

there doesn’t appear to be a roadmap for utility of digital pathology across Scotland and

implementation to date has been organic and locally focused. There is also no Project

Management support, and Gareth Bryson had indicated that this type of support would be

welcomed. DG raised that Digital Pathology was procured as a National Framework and there

is a real need to establish if we have signed a contract nationally and what the position is

should we not wish to purchase Phillips.

MG & IJ were able to comment that NHS Lothian were involved in the initial pilot which was

funded by Scottish Government however they have not yet signed up due to the concerns and

risk around the interoperability.

MC also added that there is a concern that Digital Pathology is being pushed as an answer and

it is not an answer it is merely a tool to help towards the final end state and again we have an

issue of a project progressing without any real governance around it.

JW responded to the various points raised throughout the discussion stating that the original

vision was to share images nationally and Pathologists are bought into this vision and it does

remain. The initial pilot was 1 year and JW believes that the contract is for 7 years however

was not able to comment on the current status of the contract.

PH confirmed that before anything further happens we will need to review the contract to

decide the options available and the best way to proceed.


9. AOB

PH made reference to the various discussions that have taken place at the meeting today with focus on the National LIMS and Digital Pathology and how it is now imperative that there is a national overview of the various ongoing projects. Moving forward it may be an idea to have the IT Lead for Scotland present at the LOB to give us this oversight. PH also commented on how it is clear that there needs to be a governance restructure however there is not going to be an immediate fix for this. PH is about to take over as chair for the DSG and once established within this role the idea would be to take an SBAR to the Chief Executives with a new structure for the governance. It is likely that this will not happen until early 2020. PH noted that as there are a number of project related groups it may be an idea to move the LOB to bi-monthly to allow the work required to take place in-between times. There was agreement from the group and the meetings will be changed to bi-monthly following the after the meeting in August. There was no further business raised. PH thanked everyone for their time and the meeting was

closed.

The next meeting of the LOB will take place on 29th August 2019.


Action Log

New Action(s)

Action

Ref.

Date

Action Due Date Revised

Due Date

Owner Update

M09/01 17.07.2019 Methodology required for developing of DSM model for

Histopathology.

31.07.2019 JH

M09/02 17.07.2019 Discussion to take place between the NLTP and the Regional

Leads as to who will lead on what for the Histopathology DSM

Model.

29.08.2019 JH/RL

M09/03 17.07.2019 List of disciplines and proposed dates/timelines for looking at

DSM model for all other disciplines.

31.07.2019 JH

M09/04 17.07.2019 Comms plan to be drafted for issuing to disciplines on when work

for DSM will commence for each.

29.08.2019 JH/KW

M09/05 17.07.2019 If no response from Clinisys by 24/07 speak with PH to escalate

pushing for date for Lab Centre Negotiations.

24.07.2019 ED

M09/06 17.07.2019 Request that Neil Sinclair attend next LOB to give demonstration

on new financial dashboard

29.08.2019 JH/JD

M09/07 17.07.2019 Discussions to be had re possibility of bring National LIMs

consortium to sit under LOB

29.08.2019 PH/JH

M09/08 17.07.2019 Look at possibility of submitting proposal for funding to SG

following recent request received by MM (mm will forward email

with detail to JH)

25.07.2019 JH/BB

M09/09 17.07.2019 Obtain copy of Digital Pathology contract for review 21.08.2019 JH


M09/10 17.07.2019 Speak to IT Lead for Scotland about possibility of having a seat on

the LOB going forward to ensure sight of all upcoming & ongoing

IT Projects

29.08.2019 PH

M09/11 17.07.2019 Review the need to have eHealth on the LOB 29.08.2019 PH/JH

M09/12 17.07.2019 Arrange a closed meeting to further discuss the governance and

drafting of SBAR to be submitted to CE early 2020

Mid Sept JD/JH 19/07 - Email issued to

attendees requesting

availability.

M09/13 17.07.2019 Move LOB to bi-monthly going forward. 26.07.2019 JD

M09/14 17.07.2019 Meet with Programme Manager for National LIMS Project to

discuss commonalities and how to possibly coincide the running

of the groups.

29.08.2019 JH

Ongoing Action(s)

Action Ref. Date


Due Date

Owner Update

M06/07 14.03.2019 Draft letter to be put together that can be issued to CE

around the saving in their AOP

05.06.2019 Aug 2019 KW Update will be provided to

the CE in July – Will be

included in paper to CEs in

Aug 2019

17/07 – Action on hold,

papers will be submitted to

the CE but is likely to now

be into early 2020


M06/14 14.03.2019 Draft paper for CE to be circulated with papers for next LOB

so can be finalised at June meeting for presenting to CE

post June meeting

05.06.2019 06/08/19 KW/BB Delayed until funding

confirmed as this will have

an impact on priorities

Update will be provided to

the CE in August

17/07 – Action on hold,

papers will be submitted to

the CE but is likely to now

be into early 2020

M07/02 23.04.2019 Share workforce report with LOB group 05.06.2019 Aug 2019 DS Report will be available at

end of June for circulation

02/07 – Workforce report is

not yet ready for

circulation. Will be issued

when ready

M07/03 23.04.2019 Take Benefits Realisation Tool to Clinical Leads group for

further development and update LOB at July meeting

17.07.2019 BB Still under development

M07/09 23.04.2019 Explore funding options for Paediatric Metabolic Testing

with NSD

05.06.2019 ED/LF Update to be provided at

LOB 05/06

02/07- ED has been unable

to get through to local

contacts to confirm who at

NSD would be able to

advise on this.


M07/10 23.04.2019 Clinical Leads group to look at benefits tracker from East

Region to see if can be incorporated into Benefits

Realisation Tool

17.07.2019 BB Ongoing

M07/13 23.04.2019 Further discussions to be had around NPEx Implementation

in NHS Shetland and change control to be raised if required

05.06.2019 17.07.2019 KW/LF/ED Discussion still to be

scheduled between NHS

Grampian and NHS

Shetland and NHS Orkney

02/07 – Discussion has

been scheduled 18/07

23/07 Meeting was held on

the 18th July and further

investigation work is

ongoing by eHealth teams

within Grampian &

Orkney/Shetland. Further

meeting has been

scheduled for 16/09

M08/04 05.06.2019 Meet with Clinical Leads to form SBAR articulating benefits

derived from regional work-streams for Chief Executive

Group attention and priorities for 2019/20. Ongoing

quarterly reports to keep focus and buy-in.

17.07.2019 JH/KW ongoing

M08/06 05.06.2019 LIMS – establish clear understanding of landscape around

Lab Centre and sunsetting of existing version including

potential leverage that can be applied to supplier from

joined up Board approach. SG to be party to discussions to

maximise focus.

17.07.2019 RLs ongoing


Closed Action(s)

Action Ref. Date


Due Date

Owner Update

M06/12 14.03.2019 All to look at website and provide any feedback to the team 23.04.2019 All ACTION COMPLETE

M06/15 14.03.2019 If any gaps in comms feedback to be provide to NLPT 23.04.2019 All ACTION COMPLETE

M06/06 14.03.2019 Provide number of vacancies currently within each discipline

across Scotland

23.04.2019 DS Emailed DS for update

10/04

23/04 – Item on agenda for

discussion and update given

at meeting on 23/04 –

ACTION COMPLETE


M06/22 14.03.2019 Put together brief with the amount of work required from the

disciplines for NLIIP

23.04.2019 PHI Emailed NLIIP PM (HB) for

update 10/04

23/04 Brief has now been

received and will be

circulate to the LOB

members along with the

minutes from today’s

meeting. – ACTION

COMPLETE

M06/27 14.03.2019 Speak to Business Intelligence to see what is happening with

finance data on a national level

Mid April KW 23/04 – There is now

involvement with NLIIP,

discussions need to be

taken forward in terms of

costing model – ACTION

COMPLETE

M06/05 14.03.2019 RJ to provide 2019/20 workstreams for the East region for

inclusion in the National Roadmap

29.03.2019 RJ Priorities are being

presented to ELMO 16/04,

update will provided

following the meeting

23/04 – Priorities from the

East have now been

received – ACTION

COMPLETE

M07/01 23.04.2019 Provide update at June LOB on POCT SLWG 05.06.2019 BB/MG Has been added to the

agenda for 05/06 – ACTION

CLOSED


M07/04 23.04.2019 Provide feedback on decision from Transformation Fund 05.06.2019 MM Has been added to the

agenda for 05/06 – ACTION

CLOSED

M07/11 23.04.2019 Circulate National Labs Programme leaflet in advance of

future workshops

For Info NLPT Programme leaflet will be

circulated ahead of any

future engagements /

workshops - ACTION

CLOSED

M06/04 14.03.2019 Nominations required from the group for a rep to sit on the

LIMS Procurement Board

29.03.2019 All Rep received from North &

East awaiting rep from West

09/04 – Chased West for

rep. IMcG is going to issue

comms asking for rep.

23/04 – IMcG advised she

has still not had a response

and will chase for a rep for

the board.

All reps have now been

identified – ACTION

CLOSED

M08/01 05.06.2019 IT Con project schedule to be re-phased and brought back to

LOB

17.07.2019 KW Will be added to the LOB

agenda in July – ACTION

COMPLETE

M08/02 05.06.2019 NLIIP – communication to stakeholders/networks outlining

decision to pause project

14.06.2019 KW ACTION COMPLETE


M08/05 05.06.2019 LOB to note potential impact of national AI platform 17.07.2019 JH/KW For info only – ACTION

COMPLETE

M06/08 14.03.2019 Speak to contacts at Royal College of Pathology re benefits

realisation tool and offer seat on the LOB should they wish

23.04.2019 IJ IJ has made contact but is

still awaiting a response

23/04 - D/w RCPath and a

nomination made; final

decision deferred pending

review of ToRs (see

M07/05)

02/07 – BB gave

presentation to RcPath re

benefits. It has been

decided not to offer a seat

on LOB – ACTION

COMPLETE

M06/21 14.03.2019 Defer recommendation for NLIIP until June LOB – add to the

agenda

05.06.2019 KW ACTION COMPLETE


M06/03 14.03.2019 East region to complete Proof of Concept (PoC) on costing

model & provide feedback at June meeting. KW will pick up

with DG offline about how best to proceed with this

05.06.2019 On hold KW/DG Some discussions have

taken place but currently on

hold until funding is

confirmed

02/07 – Due to the work of

NLIIP being put on hold this

now falls out with scope and

the East Region are working

on their own PoC for a

costing model – ACTION

COMPLETE

M06/28 14.03.2019 Look at priorities and workplan for 2019/20 End April 06/08/19 KW Will be raised at LOB in July

– ACTION COMPLETE

M06/29 14.03.2019 Update the roadmap/timeline at present again to the LOB in

June

05.06.2019 BC ACTION COMPLETE


M06/23 14.03.2019 Speak with Jeff Ace to discuss how to mandate the business

cases being approved throughout the boards

23.04.2019 DS Emailed DS for updated

10/04

23/04 Jeff Ace is no longer

chair of DSG, PH is going to

be chair going forward. DS

has emailed PH for further

instruction on best to

mandate business cases,

awaiting response

02/07 – Action has been

raised via Blueprint

Subgroup to look at

establishing a process.

Blueprint Subgroup will take

this forward – ACTION

CLOSED

M07/05 23.04.2019 Review ToRs for governance groups (LOB, Blueprint

Subgroup, Clinical Leads, Standardisation) under National

Labs Programme and circulate to LOB members for review

05.06.2019 IJ New approach agreed at

meeting on 5th June 2019

which will be taken forward

by PH and Clinical Leads

02/07 – ToRs and

governance reviewed by JH.

Recommendation will be

taken to LOB re

Governance Groups –

ACTION COMPLETE


M07/06 23.04.2019 Draft guidance document with clarification on what should be

submitted to each governance group i.e. Business Cases to

Blueprint Subgroup etc

05.06.2019 17.07.2019 NLPT Action will be incorporated

into Blueprint Subgroup

action of defining structure

and process for Business

Cases – ACTION

COMPLETE

M07/07 23.04.2019 Invite David Wells to present at LOB TBC 30/06/19 BB/IJ/MG IJ has invited David Wells to

attend the LOB in August –

will have discussion at LOB

on 05/06 to confirm

extending LOB in August for

David Wells presentation

decision still to be taken

02/07 – Will be added to the

agenda for LOB on 17/07 to

establish the purpose and

desired outcome of visit –

ACTION CLOSED

M07/12 23.04.2019 Develop FAQ for use at future stakeholder engagement

sessions

17.07.2019 NLPT FAQ has been developed

and will be updated

continuously as required –

ACTION CLOSED

M07/08 23.04.2019 Speak with Karen Stewart at SG re BMS Reporting 05.06.2019 ED/LF Update to be provided at

LOB 05/06

02/07- KS is now taking this

forward – ACTION

COMPLETE


M08/03 05.06.2019 Establish who has been supporting LIMS, Digital Pathology

procurement projects within NSS and determine principles

around single supplier contracts

17.07.2019 MM 17/07 – confirmed that

George Futcher from NSS

procurement is supporting

LIMS and Jim Binney was

involved in the Digitial

Pathology project from a

National Procurement

perspective – ACTION

COMPLETE .

Chair Professor Elizabeth Ireland Chief Executive Colin Sinclair

Appendix (a)

Consensus on

approach to

standardisation

July August September October November December January February March

Refine meetings

structure

Agree national

role in LIMS

programme

Plan delivery of

regional workshops

LIMS paper to

CEOs

Gain consensus on

industry problem

statements

Commence

mapping to

SNOMED CT

Deliver regional workshops

Industry pack to

LOB for sign off

Customer co-

production

workshops

Commence

standardisation

action plans

HR Risk

Assessment to

LOB

Consensus on

DSM priorities

for delivery

Industry engagement event*

Submission of

Histopathology

Model to LOB

Recommence

NLIIP delivery

NLIIP options

paper to LOB

SNOMED CT

mapping

concluded

Standardisation

action plan to

LOB

Agree industry

test bed

partnerships

Commence

industry test bed

partnerships

NPEX roll out

complete, sites

in expansion

DSM Design Toolkit issued

Governance

proposal to

CEOs

Priorities and benefits

realisation paper to

CEOs

*Contingent on Scottish Government capacity



National Laboratories Programme Minutes · PH welcomed everyone to the meeting. Introductions were done and apologies noted. 2. Minutes of Last Meeting & Matters Arising The minutes

Documents